Full-Time
OM1
51-200 employees
Healthcare technology for data analytics and outcomes
No salary listed
Senior
Boston, MA, USA
Upload your resume to see how it matches 10 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Master’s degree or PhD in public health, epidemiology, outcomes research, health economics or a relevant scientific field and at least 5 years of relevant experience
- At least 2 years experience working in a client-facing research delivery role (i.e., CRO, health tech / RWD organization)
- Exceptional knowledge and experience in RWD epidemiology, including facility with claims data, electronic health record data, and other RWD types
- Ability to communicate complex epidemiological concepts and research findings to both technical and non-technical audiences through reports, presentations, and publications
- Knowledge of healthcare data elements and common data structures
- Outstanding thinking, questioning, and listening skills; attention to detail.
- Serve as project lead on research analytic projects or in support of the project lead on larger client-facing projects
- Author protocols, reports and other study documents with independent, critical thinking to ensure quality and completeness of output, and oversee timeline for deliverables associated with analysis and reporting with input and oversight of senior staff
- Apply relevant epidemiological and outcomes research expertise to development of statistical analysis plans and interpretation of analysis output
- Independently generate content and direction for business development proposals with input from senior staff
- Lead the dissemination of research findings by authoring manuscripts and abstracts
- Familiarity with query language and/or statistical software (e.g., SQL, SAS, R)
- Expertise in leveraging unstructured clinical data to optimize real-world study design and generation of real-world evidence
- Experience with the design and execution of registries and other prospective observational studies
OM1 focuses on enhancing patient outcomes in healthcare through data analytics and artificial intelligence. The company specializes in chronic diseases, utilizing real-world data collected from sources like electronic health records and insurance claims to generate insights about treatment effectiveness in everyday settings. One of its main products, Aspen, is an automated platform that predicts patient outcomes and aids healthcare decisions. OM1 differentiates itself by leveraging AI to identify patients with specific conditions and forecast treatment results, which allows for more tailored care. The company's goal is to improve patient outcomes and support the development of new treatments by providing actionable insights to healthcare providers and pharmaceutical companies.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$172.3M
Headquarters
Boston, Massachusetts
Founded
2015
Simplify's Take
What believers are saying
- OM1's expansion into Europe enhances support for life sciences with AI-driven solutions.
- OM1's AI-powered platforms earned the 2024 North American New Product Innovation Award.
- OM1's PhenOM platform offers insights for personalized medicine and clinical research.
What critics are saying
- OM1 faces increased competition from other AI-driven healthcare analytics companies.
- Expansion into Europe may expose OM1 to new regulatory challenges.
- Reliance on real-world data poses data privacy and security risks.
What makes OM1 unique
- OM1 uses AI to identify patients with specific conditions for precise care.
- OM1's Aspen platform predicts patient outcomes for better healthcare decisions.
- OM1 combines multiple real-world data sources for deep clinical insights.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 6%2 year growth
↑ 0%BOSTON - (BUSINESS WIRE) - OM1, a leading provider of real-world data (RWD) and AI-driven insights for life sciences, today announced its expansion into Europe to better support pharmaceutical and healthcare organizations with high-quality, AI-enhanced real-world evidence (RWE) solutions.
For instance, OM1 launched its new AI-based platform in April 2023 to provide personalized information regarding clinical trials, use, risk, treatment, and diagnosis.
OM1 earns Frost & Sullivan's 2024 North American New Product Innovation Award for transforming real-world evidence analytics solutions industry with its pioneering ai-powered platforms.
OM1 appoints Catherine Richards as President.
What You Should Know:– OM1, the leader in real-world insights synthesis and evidence generation for life sciences supporting population and personalized data insights, evidence generation through advanced validated AI platforms, big deep clinical data, registries, and globally recognized thought leadership today announced the new release of its Alzheimer’s disease PremiOM dataset.– OM1 combines multiple real-world data sources – including specialists’ electronic medical records (EMR), medical and pharmacy claims, social determinants of health (SDoH), and mental health assessments – with medical language processing and advanced AI capabilities to generate deep clinical insights for patients with Alzheimer’s disease.OM1: Advancing Alzheimer’s Research with Cutting-Edge Healthcare InnovationOM1 is at the forefront of healthcare innovation, leveraging insights-driven technology and data to revolutionize personalized medicine, evidence generation, and real-world evidence (RWE) research. The company utilizes next-generation AI platforms, regulatory-grade deep longitudinal data, and globally recognized thought leadership to achieve these goals.“We know that the pathogenesis of Alzheimer’s can begin decades before clinical symptoms emerge. And, while exciting, the new disease-modifying therapies entering the market for the first time only have a modest impact on a person’s disease journey if they are already in advanced cognitive decline,” said Carl Marci, MD, Chief Clinical Officer and Managing Director of Mental Health and Neuroscience at OM1. “This, combined with the fact there is no cure, makes early detection and intervention to boost neuro-resiliency in patients even more crucial.”Led by a diverse team of scientists, engineers, researchers, and clinicians with over 30 years of experience in real-world data (RWD) and RWE, OM1 boasts a Real-World Data Cloud encompassing over one million patients. This patient data network advances research by:– Facilitating clinical trial recruitment– Uncovering prescriber trends– Modeling health economics and clinical outcomesIn addition to standard claims data, the dataset includes enriched clinical notes from over 17,000 patients within its national network of specialists treating Alzheimer’s patients. This comprehensive dataset provides deeper insights into patient journeys, enabling earlier intervention.Alzheimer’s disease, a progressive and degenerative brain disorder, impacts memory and other essential mental functions, ultimately affecting an individual’s physical, social, and financial health